I agree that this site is using cookies. You can find further informations
here
.
X
Login
My folder (
0
)
Home
About us
Home About us
Our history
Profile
Press & public relations
Friends
The library in figures
Exhibitions
Projects
Training, internships, careers
Films
Services & Information
Home Services & Information
Lending and interlibrary loans
Returns and renewals
Training and library tours
My Account
Library cards
New to the library?
Download Information
Opening hours
Learning spaces
PC, WLAN, copy, scan and print
Catalogs and collections
Home Catalogs and Collections
Rare books and manuscripts
Digital collections
Subject Areas
Our sites
Home Our sites
Central Library
Law Library (Juridicum)
BB Business and Economics (BB11)
BB Physics and Electrical Engineering
TB Engineering and Social Sciences
TB Economics and Nautical Sciences
TB Music
TB Art & Design
TB Bremerhaven
Contact the library
Home Contact the library
Staff Directory
Open access & publishing
Home Open access & publishing
Reference management: Citavi & RefWorks
Publishing documents
Open Access in Bremen
Show Desktop-Version
Toggle navigation
Champiat, S.
50
results:
Search for persons
X
Format
Online (50)
Mediatypes
E-Books (1)
Articles (Online) (32)
OpenAccess-fulltext (17)
Languages
french (9)
english (35)
Sorted by: Relevance
Sorted by: Year
?
1
Reporting and analysis of immunotherapy trials adverse even..:
Pourmir, I.
;
Nebbache, R.
;
Champiat, S.
.
Annals of Oncology. 35 (2024) 6 - p. 569-570 , 2024
Link:
https://doi.org/10.1016/..
?
2
195MO Tarlatamab in previously treated small cell lung canc..:
Hummel, H-D.
;
Champiat, S.
;
Garcia, M.E. Olmedo
...
ESMO Open. 9 (2024) - p. 102768 , 2024
Link:
https://doi.org/10.1016/..
?
3
6O Subcutaneous fat mass predicts progression-free survival..:
Delaye, M.
;
Lawrance, L.
;
Belkouchi, Y.
...
ESMO Open. 9 (2024) - p. 102261 , 2024
Link:
https://doi.org/10.1016/..
?
4
140P Stereotactic radiotherapy improves disease control in ..:
Mavrikios, A.
;
Baldini, C.
;
Loriot, Y.
...
Journal of Thoracic Oncology. 18 (2023) 4 - p. S119 , 2023
Link:
https://doi.org/10.1016/..
?
5
137P First-in-human results from a phase I dose-escalation ..:
Champiat, S.
;
Italiano, A.
;
Wagle, N.
...
Immuno-Oncology and Technology. 20 (2023) - p. 100609 , 2023
Link:
https://doi.org/10.1016/..
?
6
Infections occurring following IL6 blockade for the managem..:
Valery, M.
;
Saleh, K.
;
Ecea, R.
...
Cancer Chemotherapy and Pharmacology. 92 (2023) 3 - p. 229-233 , 2023
Link:
https://doi.org/10.1007/..
?
7
41P BRCA2 pathogenic variant (PV): A novel agnostic biomark..:
Alonso de Castro, B.
;
Gomez Randulfe, M.I.
;
Ouali, K.
...
ESMO Open. 8 (2023) 1 - p. 101007 , 2023
Link:
https://doi.org/10.1016/..
?
8
Incidence of adverse events in older patients treated with ..:
Rached, L.
;
Laparra, A.
;
Aldea, M.
...
Journal of Geriatric Oncology. 14 (2023) 8 - p. S44-S45 , 2023
Link:
https://doi.org/10.1016/..
?
9
85P Stereotactic radiotherapy improves disease control in o..:
Mavrikios, A.
;
Baldini, C.
;
Loriot, Y.
...
ESMO Open. 8 (2023) 1 - p. 100943 , 2023
Link:
https://doi.org/10.1016/..
?
10
86P Validation of the Gustave Roussy Immune (GRIm) score in..:
Herbel, N.
;
Goldschmidt, V.
;
Michot, J-M.
...
ESMO Open. 8 (2023) 1 - p. 100944 , 2023
Link:
https://doi.org/10.1016/..
?
11
Safety and efficacy of antibody drug conjugates in older pa..:
Vaz Ferreira, A.
;
Frelaut, M.
;
Pagès, A.
...
Journal of Geriatric Oncology. 14 (2023) 8 - p. S12 , 2023
Link:
https://doi.org/10.1016/..
?
12
2P Outcomes of patients with gynecological tumors harboring..:
Roussel-Simonin, C.
;
Blanc-Durand, F.
;
Bayle, A.
...
ESMO Open. 8 (2023) 1 - p. 100856 , 2023
Link:
https://doi.org/10.1016/..
?
13
Use of the Geriatric Core Dataset for older patients includ..:
Seknazi, L.
;
Goldschmidt, V.
;
Champiat, S.
...
Journal of Geriatric Oncology. 13 (2022) 8 - p. S66 , 2022
Link:
https://doi.org/10.1016/..
?
14
OA12.05 Phase 1 Updated Exploration and First Expansion Dat..:
Borghaei, H.
;
Paz-Ares, L.
;
Johnson, M.
...
Journal of Thoracic Oncology. 17 (2022) 9 - p. S33 , 2022
Link:
https://doi.org/10.1016/..
?
15
147P Characterizing CRS in phase I study of DLL3-targeted T..:
Champiat, S.
;
Boyer, M.
;
Paz-Ares, L.
...
Immuno-Oncology and Technology. 16 (2022) - p. 100259 , 2022
Link:
https://doi.org/10.1016/..
1-15